Good news for people looking for more affordable options to help them lose weight and keep it off! The U.S. Food and Drug Administration (FDA) approved a generic version of Saxenda, a commonly prescribed glucagon-like peptide-1 receptor agonist (GLP-1). “With this approval, and by launching a generic for Saxenda (liraglutide injection), we will provide patients […] The post FDA approves generic Saxenda appeared first on The Checkup.| The Checkup
Wegovy (semaglutide) is a brand-name prescription drug known as a glucagon-like peptide-1 (GLP-1) receptor agonist. Intended to be used in conjunction with diet and physical activity, Wegovy is approved by the Food and Drug Administration (FDA) for long-term weight loss and weight management in adults and children ages 12 years and older with obesity, and […] The post Does Wegovy cause headaches? Here’s what we know appeared first on The Checkup.| The Checkup
Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s room for many MASH drugs with the treatment landscape expected to shape up to include combinations of therapies bringing different approaches to this fatty liver disease.| MedCity News
Here are five guidelines to help employers balance health outcomes and financial responsibility to ensure that GLP-1 coverage is effective, affordable, and aligned with improved health and workforce well-being for employees and their families.| MedCity News
The CEO of a $7.8 billion asset manager says his firm is investing in three companies poised to drive transformative advancements in healthcare, financial data and AI.| The Daily Hodl
OMNY Health — a national data ecosystem that facilitates biotech and medical research — launched a data network consisting of EHR data from more than 645,000 GLP-1 users. The data network seeks to give OMNY’s life sciences and health system partners a vast source of GLP-1 data that is related to patient demographics and social determinants of health.| MedCity News